Loading…

Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus

Among fatty acid-binding proteins (FABPs), secreted forms of FABP4 and FABP5, which are expressed in adipocytes and macrophages, act as bioactive molecules. We investigated concentrations of FABP4 and FABP5 in patients with type 2 diabetes mellitus. As a sub-analysis study of the Randomized Evaluati...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) 2020-09, Vol.11, p.575557-575557
Main Authors: Furuhashi, Masato, Sakuma, Ichiro, Morimoto, Takeshi, Higashiura, Yukimura, Sakai, Akiko, Matsumoto, Megumi, Sakuma, Mio, Shimabukuro, Michio, Nomiyama, Takashi, Arasaki, Osamu, Node, Koichi, Ueda, Shinichiro
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c465t-278f7d12b10a78ec7fdea57747914adea85b789e295b9c2b0237091436953cb83
cites cdi_FETCH-LOGICAL-c465t-278f7d12b10a78ec7fdea57747914adea85b789e295b9c2b0237091436953cb83
container_end_page 575557
container_issue
container_start_page 575557
container_title Frontiers in endocrinology (Lausanne)
container_volume 11
creator Furuhashi, Masato
Sakuma, Ichiro
Morimoto, Takeshi
Higashiura, Yukimura
Sakai, Akiko
Matsumoto, Megumi
Sakuma, Mio
Shimabukuro, Michio
Nomiyama, Takashi
Arasaki, Osamu
Node, Koichi
Ueda, Shinichiro
description Among fatty acid-binding proteins (FABPs), secreted forms of FABP4 and FABP5, which are expressed in adipocytes and macrophages, act as bioactive molecules. We investigated concentrations of FABP4 and FABP5 in patients with type 2 diabetes mellitus. As a sub-analysis study of the Randomized Evaluation of Anagliptin vs. Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial, 256 patients (male/female: 146/110, age: 68 ± 10 years) with type 2 diabetes mellitus and dyslipidemia who were receiving statin therapy were recruited. Patients who had been treated with a thiazolidinedione were excluded. Several drugs which may modulate FABP4 levels including statins, dipeptidyl peptidase-4 inhibitors and angiotensin II receptor blockers had been administered in 100, 81, and 51% of the recruited patients, respectively. The level of FABP4, but not that of FABP5, was significantly higher in females than in males. Multivariable linear regression analysis demonstrated that waist circumference (β = 0.21), estimated glomerular filtration rate (β = -0.31), triglycerides (β = 0.16), and FABP5 (β = 0.39) were independent predictors of FABP4 level after adjusting age and sex. On the other hand, FABP5 level was independently associated with levels of FABP4 (β = 0.57) and high-density lipoprotein (HDL) cholesterol (β = -0.12). Concentrations of FABP4 and FABP5 are independent predictors of each other in patients with type 2 diabetes mellitus. There are distinct independent associations of FABP4 with renal dysfunction, adiposity and hypertriglyceridemia and there is a distinct independent association of FABP5 with a low HDL cholesterol level in type 2 diabetic patients with dyslipidemia at high risks for cardiovascular disease who are receiving statin therapy.
doi_str_mv 10.3389/fendo.2020.575557
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_3f83f02886a94ad6981bbf23916451ba</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_3f83f02886a94ad6981bbf23916451ba</doaj_id><sourcerecordid>2452098248</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-278f7d12b10a78ec7fdea57747914adea85b789e295b9c2b0237091436953cb83</originalsourceid><addsrcrecordid>eNpVkU9PnCEQxklTU436AXppOPayK39f4NJkq7VuYqMHTY8EeEEx78IW2CZ--7K71igXJjPP_GYyDwCfMZpTKtVZ8GnMc4IImnPBORcfwBEeBjYjVJGPb-JDcFrrE-qPIayU_AQOKUUCK0mOQFqm0a87yqcGTRrhRawtJtfgotbsomkxpwpzgJeL77dsJ9lGHP6O7RH-8s3YPEUHb00xK998qTAmePe89pB0mLE9V7tummLb1BNwEMxU_enLfwzuL3_cnV_Nrm9-Ls8X1zPHBt5mRMggRkwsRkZI70QYveFCMKEwMz2W3AqpPFHcKkcsIlSgXqKD4tRZSY_Bcs8ds3nS6xJXpjzrbKLeJXJ50Ka06CavaZA0ICLlYFRnD0pia0M_HB4Yx9Z01rc9a72xKz-6fqlipnfQ95UUH_VD_qsFp5Kz7TJfXwAl_9n42vQqVtcvYpLPm6oJ4wR1N3ZSvJe6kmstPryOwUhvbdc72_XWdr23vfd8ebvfa8d_k-k_m26ojQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2452098248</pqid></control><display><type>article</type><title>Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus</title><source>Open Access: PubMed Central</source><creator>Furuhashi, Masato ; Sakuma, Ichiro ; Morimoto, Takeshi ; Higashiura, Yukimura ; Sakai, Akiko ; Matsumoto, Megumi ; Sakuma, Mio ; Shimabukuro, Michio ; Nomiyama, Takashi ; Arasaki, Osamu ; Node, Koichi ; Ueda, Shinichiro</creator><creatorcontrib>Furuhashi, Masato ; Sakuma, Ichiro ; Morimoto, Takeshi ; Higashiura, Yukimura ; Sakai, Akiko ; Matsumoto, Megumi ; Sakuma, Mio ; Shimabukuro, Michio ; Nomiyama, Takashi ; Arasaki, Osamu ; Node, Koichi ; Ueda, Shinichiro</creatorcontrib><description>Among fatty acid-binding proteins (FABPs), secreted forms of FABP4 and FABP5, which are expressed in adipocytes and macrophages, act as bioactive molecules. We investigated concentrations of FABP4 and FABP5 in patients with type 2 diabetes mellitus. As a sub-analysis study of the Randomized Evaluation of Anagliptin vs. Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial, 256 patients (male/female: 146/110, age: 68 ± 10 years) with type 2 diabetes mellitus and dyslipidemia who were receiving statin therapy were recruited. Patients who had been treated with a thiazolidinedione were excluded. Several drugs which may modulate FABP4 levels including statins, dipeptidyl peptidase-4 inhibitors and angiotensin II receptor blockers had been administered in 100, 81, and 51% of the recruited patients, respectively. The level of FABP4, but not that of FABP5, was significantly higher in females than in males. Multivariable linear regression analysis demonstrated that waist circumference (β = 0.21), estimated glomerular filtration rate (β = -0.31), triglycerides (β = 0.16), and FABP5 (β = 0.39) were independent predictors of FABP4 level after adjusting age and sex. On the other hand, FABP5 level was independently associated with levels of FABP4 (β = 0.57) and high-density lipoprotein (HDL) cholesterol (β = -0.12). Concentrations of FABP4 and FABP5 are independent predictors of each other in patients with type 2 diabetes mellitus. There are distinct independent associations of FABP4 with renal dysfunction, adiposity and hypertriglyceridemia and there is a distinct independent association of FABP5 with a low HDL cholesterol level in type 2 diabetic patients with dyslipidemia at high risks for cardiovascular disease who are receiving statin therapy.</description><identifier>ISSN: 1664-2392</identifier><identifier>EISSN: 1664-2392</identifier><identifier>DOI: 10.3389/fendo.2020.575557</identifier><identifier>PMID: 33071982</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>adipokine ; diabetes mellitus ; dipeptidyl peptidase-4 inhibitor ; Endocrinology ; fatty acid-binding protein ; stain</subject><ispartof>Frontiers in endocrinology (Lausanne), 2020-09, Vol.11, p.575557-575557</ispartof><rights>Copyright © 2020 Furuhashi, Sakuma, Morimoto, Higashiura, Sakai, Matsumoto, Sakuma, Shimabukuro, Nomiyama, Arasaki, Node and Ueda.</rights><rights>Copyright © 2020 Furuhashi, Sakuma, Morimoto, Higashiura, Sakai, Matsumoto, Sakuma, Shimabukuro, Nomiyama, Arasaki, Node and Ueda. 2020 Furuhashi, Sakuma, Morimoto, Higashiura, Sakai, Matsumoto, Sakuma, Shimabukuro, Nomiyama, Arasaki, Node and Ueda</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-278f7d12b10a78ec7fdea57747914adea85b789e295b9c2b0237091436953cb83</citedby><cites>FETCH-LOGICAL-c465t-278f7d12b10a78ec7fdea57747914adea85b789e295b9c2b0237091436953cb83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538548/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538548/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33071982$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Furuhashi, Masato</creatorcontrib><creatorcontrib>Sakuma, Ichiro</creatorcontrib><creatorcontrib>Morimoto, Takeshi</creatorcontrib><creatorcontrib>Higashiura, Yukimura</creatorcontrib><creatorcontrib>Sakai, Akiko</creatorcontrib><creatorcontrib>Matsumoto, Megumi</creatorcontrib><creatorcontrib>Sakuma, Mio</creatorcontrib><creatorcontrib>Shimabukuro, Michio</creatorcontrib><creatorcontrib>Nomiyama, Takashi</creatorcontrib><creatorcontrib>Arasaki, Osamu</creatorcontrib><creatorcontrib>Node, Koichi</creatorcontrib><creatorcontrib>Ueda, Shinichiro</creatorcontrib><title>Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus</title><title>Frontiers in endocrinology (Lausanne)</title><addtitle>Front Endocrinol (Lausanne)</addtitle><description>Among fatty acid-binding proteins (FABPs), secreted forms of FABP4 and FABP5, which are expressed in adipocytes and macrophages, act as bioactive molecules. We investigated concentrations of FABP4 and FABP5 in patients with type 2 diabetes mellitus. As a sub-analysis study of the Randomized Evaluation of Anagliptin vs. Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial, 256 patients (male/female: 146/110, age: 68 ± 10 years) with type 2 diabetes mellitus and dyslipidemia who were receiving statin therapy were recruited. Patients who had been treated with a thiazolidinedione were excluded. Several drugs which may modulate FABP4 levels including statins, dipeptidyl peptidase-4 inhibitors and angiotensin II receptor blockers had been administered in 100, 81, and 51% of the recruited patients, respectively. The level of FABP4, but not that of FABP5, was significantly higher in females than in males. Multivariable linear regression analysis demonstrated that waist circumference (β = 0.21), estimated glomerular filtration rate (β = -0.31), triglycerides (β = 0.16), and FABP5 (β = 0.39) were independent predictors of FABP4 level after adjusting age and sex. On the other hand, FABP5 level was independently associated with levels of FABP4 (β = 0.57) and high-density lipoprotein (HDL) cholesterol (β = -0.12). Concentrations of FABP4 and FABP5 are independent predictors of each other in patients with type 2 diabetes mellitus. There are distinct independent associations of FABP4 with renal dysfunction, adiposity and hypertriglyceridemia and there is a distinct independent association of FABP5 with a low HDL cholesterol level in type 2 diabetic patients with dyslipidemia at high risks for cardiovascular disease who are receiving statin therapy.</description><subject>adipokine</subject><subject>diabetes mellitus</subject><subject>dipeptidyl peptidase-4 inhibitor</subject><subject>Endocrinology</subject><subject>fatty acid-binding protein</subject><subject>stain</subject><issn>1664-2392</issn><issn>1664-2392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU9PnCEQxklTU436AXppOPayK39f4NJkq7VuYqMHTY8EeEEx78IW2CZ--7K71igXJjPP_GYyDwCfMZpTKtVZ8GnMc4IImnPBORcfwBEeBjYjVJGPb-JDcFrrE-qPIayU_AQOKUUCK0mOQFqm0a87yqcGTRrhRawtJtfgotbsomkxpwpzgJeL77dsJ9lGHP6O7RH-8s3YPEUHb00xK998qTAmePe89pB0mLE9V7tummLb1BNwEMxU_enLfwzuL3_cnV_Nrm9-Ls8X1zPHBt5mRMggRkwsRkZI70QYveFCMKEwMz2W3AqpPFHcKkcsIlSgXqKD4tRZSY_Bcs8ds3nS6xJXpjzrbKLeJXJ50Ka06CavaZA0ICLlYFRnD0pia0M_HB4Yx9Z01rc9a72xKz-6fqlipnfQ95UUH_VD_qsFp5Kz7TJfXwAl_9n42vQqVtcvYpLPm6oJ4wR1N3ZSvJe6kmstPryOwUhvbdc72_XWdr23vfd8ebvfa8d_k-k_m26ojQ</recordid><startdate>20200923</startdate><enddate>20200923</enddate><creator>Furuhashi, Masato</creator><creator>Sakuma, Ichiro</creator><creator>Morimoto, Takeshi</creator><creator>Higashiura, Yukimura</creator><creator>Sakai, Akiko</creator><creator>Matsumoto, Megumi</creator><creator>Sakuma, Mio</creator><creator>Shimabukuro, Michio</creator><creator>Nomiyama, Takashi</creator><creator>Arasaki, Osamu</creator><creator>Node, Koichi</creator><creator>Ueda, Shinichiro</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200923</creationdate><title>Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus</title><author>Furuhashi, Masato ; Sakuma, Ichiro ; Morimoto, Takeshi ; Higashiura, Yukimura ; Sakai, Akiko ; Matsumoto, Megumi ; Sakuma, Mio ; Shimabukuro, Michio ; Nomiyama, Takashi ; Arasaki, Osamu ; Node, Koichi ; Ueda, Shinichiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-278f7d12b10a78ec7fdea57747914adea85b789e295b9c2b0237091436953cb83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>adipokine</topic><topic>diabetes mellitus</topic><topic>dipeptidyl peptidase-4 inhibitor</topic><topic>Endocrinology</topic><topic>fatty acid-binding protein</topic><topic>stain</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Furuhashi, Masato</creatorcontrib><creatorcontrib>Sakuma, Ichiro</creatorcontrib><creatorcontrib>Morimoto, Takeshi</creatorcontrib><creatorcontrib>Higashiura, Yukimura</creatorcontrib><creatorcontrib>Sakai, Akiko</creatorcontrib><creatorcontrib>Matsumoto, Megumi</creatorcontrib><creatorcontrib>Sakuma, Mio</creatorcontrib><creatorcontrib>Shimabukuro, Michio</creatorcontrib><creatorcontrib>Nomiyama, Takashi</creatorcontrib><creatorcontrib>Arasaki, Osamu</creatorcontrib><creatorcontrib>Node, Koichi</creatorcontrib><creatorcontrib>Ueda, Shinichiro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in endocrinology (Lausanne)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Furuhashi, Masato</au><au>Sakuma, Ichiro</au><au>Morimoto, Takeshi</au><au>Higashiura, Yukimura</au><au>Sakai, Akiko</au><au>Matsumoto, Megumi</au><au>Sakuma, Mio</au><au>Shimabukuro, Michio</au><au>Nomiyama, Takashi</au><au>Arasaki, Osamu</au><au>Node, Koichi</au><au>Ueda, Shinichiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus</atitle><jtitle>Frontiers in endocrinology (Lausanne)</jtitle><addtitle>Front Endocrinol (Lausanne)</addtitle><date>2020-09-23</date><risdate>2020</risdate><volume>11</volume><spage>575557</spage><epage>575557</epage><pages>575557-575557</pages><issn>1664-2392</issn><eissn>1664-2392</eissn><abstract>Among fatty acid-binding proteins (FABPs), secreted forms of FABP4 and FABP5, which are expressed in adipocytes and macrophages, act as bioactive molecules. We investigated concentrations of FABP4 and FABP5 in patients with type 2 diabetes mellitus. As a sub-analysis study of the Randomized Evaluation of Anagliptin vs. Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial, 256 patients (male/female: 146/110, age: 68 ± 10 years) with type 2 diabetes mellitus and dyslipidemia who were receiving statin therapy were recruited. Patients who had been treated with a thiazolidinedione were excluded. Several drugs which may modulate FABP4 levels including statins, dipeptidyl peptidase-4 inhibitors and angiotensin II receptor blockers had been administered in 100, 81, and 51% of the recruited patients, respectively. The level of FABP4, but not that of FABP5, was significantly higher in females than in males. Multivariable linear regression analysis demonstrated that waist circumference (β = 0.21), estimated glomerular filtration rate (β = -0.31), triglycerides (β = 0.16), and FABP5 (β = 0.39) were independent predictors of FABP4 level after adjusting age and sex. On the other hand, FABP5 level was independently associated with levels of FABP4 (β = 0.57) and high-density lipoprotein (HDL) cholesterol (β = -0.12). Concentrations of FABP4 and FABP5 are independent predictors of each other in patients with type 2 diabetes mellitus. There are distinct independent associations of FABP4 with renal dysfunction, adiposity and hypertriglyceridemia and there is a distinct independent association of FABP5 with a low HDL cholesterol level in type 2 diabetic patients with dyslipidemia at high risks for cardiovascular disease who are receiving statin therapy.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>33071982</pmid><doi>10.3389/fendo.2020.575557</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-2392
ispartof Frontiers in endocrinology (Lausanne), 2020-09, Vol.11, p.575557-575557
issn 1664-2392
1664-2392
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_3f83f02886a94ad6981bbf23916451ba
source Open Access: PubMed Central
subjects adipokine
diabetes mellitus
dipeptidyl peptidase-4 inhibitor
Endocrinology
fatty acid-binding protein
stain
title Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T04%3A31%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Independent%20and%20Distinct%20Associations%20of%20FABP4%20and%20FABP5%20With%20Metabolic%20Parameters%20in%20Type%202%20Diabetes%20Mellitus&rft.jtitle=Frontiers%20in%20endocrinology%20(Lausanne)&rft.au=Furuhashi,%20Masato&rft.date=2020-09-23&rft.volume=11&rft.spage=575557&rft.epage=575557&rft.pages=575557-575557&rft.issn=1664-2392&rft.eissn=1664-2392&rft_id=info:doi/10.3389/fendo.2020.575557&rft_dat=%3Cproquest_doaj_%3E2452098248%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c465t-278f7d12b10a78ec7fdea57747914adea85b789e295b9c2b0237091436953cb83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2452098248&rft_id=info:pmid/33071982&rfr_iscdi=true